RNA | MedPath Search

Found 452 clinical trials|View Analysis

Sort by:

Need a comprehensive medical report on "RNA"?

Analyze the latest clinical research and treatment options

Summarize scientific findings from medical journals

Study of Tumor RNA Disruption Assay™ (RDA)

Not Applicable

Terminated

Conditions: Breast Neoplasms

Interventions: Other: Tumor RNA Disruption Assay™ (RDA)

First Posted Date: 2014-09-12

Last Posted Date: 2017-10-26

Lead Sponsor: University of Toronto

Target Recruit Count: 1

Registration Number: NCT02239315

Locations: 🇨🇦
Hamilton Health Sciences Juravinski Cancer Centre, Hamilton, Ontario, Canada
🇨🇦
Sunnybrook Health Sciences Odette Cancer Centre, Toronto, Ontario, Canada
🇨🇦
St Michael's Hospital, Toronto, Ontario, Canada

and more 1 locations

Immunogenicity, Safety and Tolerability of a Plant-Derived Seasonal VLP Quadrivalent Influenza Vaccine in the Elderly Population

Phase 2

Completed

Conditions: Respiratory Tract Diseases
Respiratory Tract Infections
RNA Virus Infections
Virus Diseases

Interventions: Biological: Non-adjuvanted medium dose of quadrivalent VLP vaccine
Biological: Adjuvanted high dose of quadrivalent VLP vaccine
Biological: Non-adjuvanted low dose of quadrivalent VLP vaccine
Biological: Placebo
Biological: Non-adjuvanted high dose of quadrivalent VLP vaccine
Biological: Adjuvanted low dose of quadrivalent VLP vaccine

First Posted Date: 2014-09-10

Last Posted Date: 2019-11-01

Lead Sponsor: Medicago

Target Recruit Count: 450

Registration Number: NCT02236052

Locations: 🇨🇦
MUHC-Vaccine Study Centre, Pierrefonds, Quebec, Canada
🇨🇦
inVentiv Health Clinique, Québec, Canada
🇨🇦
Centre de recherche-CHU de Québec, Québec, Canada

Immunogenicity, Safety and Tolerability of a Plant-Derived Seasonal Virus-Like-Particle Quadrivalent Influenza Vaccine in Adults

Phase 2

Completed

Conditions: Virus Diseases
RNA Virus Infections
Respiratory Tract Diseases
Respiratory Tract Infections

Interventions: Biological: Low dose of quadrivalent VLP vaccine
Biological: Medium dose of quadrivalent VLP vaccine
Biological: High dose of quadrivalent VLP vaccine
Biological: Placebo

First Posted Date: 2014-09-08

Last Posted Date: 2019-11-13

Lead Sponsor: Medicago

Target Recruit Count: 300

Registration Number: NCT02233816

Locations: 🇺🇸
Broward Research Group, Hollywood, Florida, United States
🇺🇸
Miami Research Associates, Miami, Florida, United States

Comparison of Human Papillomavirus Integrated DNA and Messenger RNA in Cervical Neoplasia

Completed

Conditions: Cervical Intraepithelial Neoplasia

First Posted Date: 2014-07-23

Last Posted Date: 2014-07-23

Lead Sponsor: Cathay General Hospital

Target Recruit Count: 250

Registration Number: NCT02198365

Locations: 🇨🇳
Cathay General Hospital, Taipei, Taiwan

RNA Disruption Assay (RDA) Response Prediction in Neoadjuvant Chemotherapy Breast Cancer Treatment

Phase 2

Completed

Conditions: Invasive Breast Cancer

Interventions: Device: Tumor RDA biopsy

First Posted Date: 2014-07-15

Last Posted Date: 2015-02-04

Lead Sponsor: Jewish General Hospital

Target Recruit Count: 30

Registration Number: NCT02190227

Locations: 🇨🇦
Jewish General Hospital, Montreal, Quebec, Canada

Vaccine Therapy Before Surgery in Treating Patients With Localized Kidney Cancer

Not Applicable

Terminated

Conditions: Stage II Renal Cell Cancer
Recurrent Renal Cell Carcinoma
Stage I Renal Cell Cancer

Interventions: Other: Laboratory Biomarker Analysis
Procedure: Nephrectomy
Biological: Renal Cell Carcinoma/CD40L RNA-Transfected Autologous Dendritic Cell Vaccine AGS-003

First Posted Date: 2014-06-23

Last Posted Date: 2020-07-07

Lead Sponsor: Roswell Park Cancer Institute

Target Recruit Count: 5

Registration Number: NCT02170389

Locations: 🇺🇸
Roswell Park Cancer Institute, Buffalo, New York, United States

Registry Measuring the Impact of Adding RNA Expression Testing on Referral Decisions in Early Stage Lung Cancer Patients and Assessing the Disease-free Survival With Long-term Follow-up

Terminated

Conditions: Lung Cancer
Lung Adenocarcinoma
NSCLC

First Posted Date: 2014-04-24

Last Posted Date: 2017-09-05

Lead Sponsor: Myriad Genetic Laboratories, Inc.

Target Recruit Count: 227

Registration Number: NCT02121925

Registry Measuring Impact of RNA Expression Testing on Treatment Decisions in Early Stage Lung Cancer and Assessing the Disease-free Survival With Long-term Follow-up (ONC006)

Terminated

Conditions: NSCLC
NSCLC Adenocarcinoma
Lung Cancer

First Posted Date: 2014-04-24

Last Posted Date: 2017-09-05

Lead Sponsor: Myriad Genetic Laboratories, Inc.

Target Recruit Count: 44

Registration Number: NCT02121899

Vitamin D and Vitamin B12 Supplementation With Pegylated Interferon-Alfa Plus Ribavirin for Treating Chronic Hepatitis C

Phase 4

Terminated

Conditions: RNA Virus Infections
Flaviviridae Infections
Hepatitis C
Hepatitis C, Chronic

Interventions: Drug: Vitamin D
Drug: Vitamin B 12

First Posted Date: 2014-04-22

Last Posted Date: 2016-08-24

Lead Sponsor: Federal University of São Paulo

Target Recruit Count: 85

Registration Number: NCT02120274

Locations: 🇧🇷
Outpatient Clinic of Viral Hepatitis (NUPAIG), São Paulo, Brazil

Transforming Research and Clinical Knowledge in Traumatic Brain Injury

Completed

Conditions: Traumatic Brain Injury

Interventions: Behavioral: In-Person Outcome Assessment
Behavioral: Phone Outcome Assessment
Procedure: 3T Magnetic Resonance Imaging (MRI)
Procedure: Blood Draw for Plasma, DNA, Serum, RNA

First Posted Date: 2014-04-21

Last Posted Date: 2020-09-16

Lead Sponsor: University of California, San Francisco

Target Recruit Count: 2996

Registration Number: NCT02119182

Locations: 🇺🇸
Spaulding Rehabilitation Hospital, Charlestown, Massachusetts, United States
🇺🇸
Virginia Commonwealth University, Richmond, Virginia, United States
🇺🇸
Medical College of Wisconsin, Milwaukee, Wisconsin, United States

and more 20 locations